« Back to Record
Citation APA

Adès, L., Boehrer, S., Prebet, T., Beyne-Rauzy, O., Legros, L., Ravoet, C., Dreyfus, F., Stamatoullas, A., Chaury, M. P., Delaunay, J., Laurent, G., Vey, N., Burcheri, S., Mbida, R.-M., Hoarau, N., Gardin, C., & Fenaux, P. (2009). Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood, 113(17), 3947-3952. doi:10.1182/blood-2008-08-175778


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/119815

Adès, L., Boehrer, S., Prebet, T., Beyne-Rauzy, O., Legros, L., Ravoet, C., Dreyfus, F., Stamatoullas, A., Chaury, M. P., Delaunay, J., Laurent, G., Vey, N., Burcheri, S., Mbida, R.-M., Hoarau, N., Gardin, C., & Fenaux, P. (2009). Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood, 113(17), 3947-3952. doi:10.1182/blood-2008-08-175778